(RLMD) Relmada Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 725m USD | Total Return: 1145.6% in 12m

Antidepressants, Bladder Cancer Drugs, Neurosteroids, Clinical Therapeutics
Total Rating 45
Safety 59
Buy Signal -0.06
Biotechnology
Industry Rotation: -15.9
Market Cap: 725M
Avg Turnover: 6.76M
Risk 3d forecast
Volatility101%
VaR 5th Pctl13.6%
VaR vs Median-23.6%
Reward TTM
Sharpe Ratio2.61
Rel. Str. IBD99.9
Rel. Str. Peer Group99.4
Character TTM
Beta0.529
Beta Downside-0.349
Hurst Exponent0.474
Drawdowns 3y
Max DD96.30%
CAGR/Max DD0.25
CAGR/Mean DD0.50

Warnings

Share dilution 184.8% YoY

Altman Z'' -15.00 < 1.0 - financial distress zone

Tailwinds

Supp Ema20, Leader

Description: RLMD Relmada Therapeutics

Relmada Therapeutics (RLMD) is a clinical-stage biotechnology firm headquartered in Coral Gables, Florida, specialized in developing therapies for oncology and central nervous system disorders. Its primary pipeline includes NDV-01, an intravesical formulation currently in Phase 2 trials for aggressive non-muscle invasive bladder cancer, and Sepranolone, a neurosteroid targeting conditions linked to GABAergic activity such as Tourette syndrome and Prader-Willi syndrome.

The company operates within the high-risk pharmaceutical sector, where business models center on the clinical validation of intellectual property and strategic partnerships, such as Relmadas existing agreements with Asarina Pharma AB and Trigone. Clinical-stage biotech firms typically undergo long development cycles and face significant regulatory hurdles before achieving commercialization or revenue generation.

Evaluating clinical trial timelines and partnership structures on ValueRay can provide deeper insight into the companys valuation.

Headlines to Watch Out For
  • Phase 2 clinical trial results for NDV-01 impact bladder cancer market valuation
  • Regulatory approval milestones for Sepranolone determine future neurosteroid therapy revenue potential
  • Research and development expenditures influence cash runway and capital raising needs
  • Strategic partnership execution with Asarina Pharma affects pipeline commercialization prospects
  • Clinical data readouts for Tourette and Prader-Willi syndromes drive investor sentiment
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.18 > 0.02 and ΔFCF/TA 187.0 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.18 > 3% & CFO -42.8m > Net Income -58.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 18.26 > 1.5 & < 3
Outstanding Shares: last quarter (86.6m) vs 12m ago 184.8% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.95 (Total Current Assets 235.3m - Total Current Liabilities 12.9m) / Total Assets 235.4m
B: -3.05 (Retained Earnings -717.3m / Total Assets 235.4m)
C: -0.46 (EBIT TTM -60.3m / Avg Total Assets 131.5m)
D: -43.13 (Book Value of Equity -717.2m / Total Liabilities 16.6m)
Altman-Z'' Score: -52.10 = D
What is the price of RLMD shares? As of May 19, 2026, the stock is trading at USD 6.34 with a total of 2,393,961 shares traded.
Over the past week, the price has changed by -13.86%, over one month by -13.98%, over three months by +55.39% and over the past year by +1145.58%.
Is RLMD a buy, sell or hold? Relmada Therapeutics has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold RLMD.
  • StrongBuy: 0
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RLMD price?
Analysts Target Price 12.8 101.9%
Relmada Therapeutics (RLMD) - Fundamental Data Overview as of 19 May 2026
P/S = 9001.8951
P/B = 8.887
Revenue TTM = 0.0 USD
EBIT TTM = -60.3m USD
EBITDA TTM = -60.3m USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = unknown
 Net Debt = -9.78m USD (from netDebt column, last quarter)
Enterprise Value = 490.8m USD (724.8m + (null Debt) - CCE 234.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -60.3m / Interest Expense TTM 0.0)
 EV/FCF = -11.47x (Enterprise Value 490.8m / FCF TTM -42.8m)
FCF Yield = -8.72% (FCF TTM -42.8m / Enterprise Value 490.8m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 2.09 (Enterprise Value 490.8m / Total Assets 235.4m)
 Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
 Taxrate = 21.0% (US default 21%)
NOPAT = -47.7m (EBIT -60.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.26 (Total Current Assets 235.3m / Total Current Liabilities 12.9m)
 Debt / Equity = unknown (Debt none)
 Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -9.78m / EBITDA -60.3m)
 Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -9.78m / FCF TTM -42.8m)
 Total Stockholder Equity = 82.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.77% (Net Income -58.9m / Total Assets 235.4m)
RoE = -71.22% (Net Income TTM -58.9m / Total Stockholder Equity 82.7m)
RoCE = -27.12% (EBIT -60.3m / Capital Employed (Total Assets 235.4m - Current Liab 12.9m))
 RoIC = -127.8% (out of range, set to none) (NOPAT -47.7m / Invested Capital 37.3m)
 WACC = 7.84% (E(724.8m)/V(724.8m) * Re(7.84%) + (debt-free company))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 95.45 | Cagr: 59.95%
 [DCF] Fair Price = unknown (Cash Flow -42.8m)
 EPS Correlation: 94.86 | EPS CAGR: 83.54% | SUE: 1.16 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.19 | Chg30d=N/A | Revisions=N/A | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=N/A | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.41 | Chg30d=-13.89% | Revisions=-20% | GrowthEPS=+62.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.41 | Chg30d=+10.87% | Revisions=+20% | GrowthEPS=+0.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%